-
Middle East fuel crunch drives solar push in tiny Fiji
-
Tech firms bear brunt of selling as Asian stocks drop
-
Indian rappers use music to sound climate alarm
-
Reese scores 30 as Dream stun Valkyries to level WNBA finals
-
Japan probe on its way to Mars moon
-
Horror and disbelief after lawmaker attacked in rural Australia
-
Lula or Bolsonaro's son? Brazil makes a final choice
-
Ukraine races to secure energy supplies ahead of winter
-
EU unveils strategy to boost Arctic presence
-
Vote count begins in Alberta secession referedum, testing Canada unity
-
How recent controversies have rocked the US death penalty debate
-
Ukraine claims US missile holdup as Trump floats summit without Zelensky
-
Adams facing long injury layoff as Rams' problems deepen
-
Detained Suu Kyi receives UK royal package: Myanmar govt
-
US judge orders Saudi engineer held in OpenAI case
-
Japan successfully launches probe in historic Mars moon mission
-
Maddison sparkles as Spurs end Premier League winless run
-
US to auction deep sea mining leases off American Samoa
-
Maddison sparkles on Spurs return as win drought ends
-
Australian lawmaker hurt in car attack underwent surgery overnight: PM
-
Trump says ready to meet with Putin and Xi in China
-
Japan launches rocket for potential world first Mars moon mission
-
The young lawmaker making Brazil's Lula 'king of the selfie'
-
Ethiopia PM warns Eritrea of 'severe consequences' if supports enemies
-
Christiane Amanpour to leave CNN after 43 years
-
Boland grabs opportunity for Australia as South Africa struggle in second Test
-
Ronaldo handed 30-day suspension after walking out on Portugal
-
Ronaldo handed 30-day suspension: Portuguese federation
-
Netanyahu basks in Trump endorsement week before election
-
France announces curfews as government grapples with unrest
-
Saudi airport closure disrupts life in kingdom's capital
-
Boland sets pace as South Africa struggle
-
Ramaphosa tells South Africa to prepare for loss of US-Africa trade deal
-
Ukraine on back foot as Kremlin moots US, China meeting
-
France presses resale platforms to remove 'stolen' goods after unrest
-
'Stay home!': Tourists find themselves in a France convulsed by protests
-
Yamal v PSG: Ballon d'Or backdrop to Champions League showdown
-
Kenyan cult leader guilty on all charges over 191 starvation deaths
-
Araujo says too soon to talk about permanent Liverpool move
-
Eagles star Hurts to miss rest of NFL season: reports
-
US wants to be 'strong partner' for central Asia: Rubio
-
Oil-rich Alberta votes on Canada breakup
-
'Special' to face friend Perez in Champions League, says Liverpool's Iraola
-
Israel announces arrests after West Bank settler attacks on Westerners
-
Monitor says Indonesia fires have burned nearly two million hectares
-
Guehi insists players have 'trust and belief' in Man City after charges
-
French PM says could declare state of emergency over unrest 'if needed'
-
UN climate panel head wants swift end to deadlock over key scientific report
-
Albanian PM warns of 'red line' after days of unrest
-
PM calls for curfews in France as govt grapples with unrest
Moderna says US refusing to review mRNA-based flu shot
Vaccine manufacturer Moderna said Tuesday the US Food and Drug Administration was refusing to review an application for its first mRNA-based flu shot.
The move comes as the current iteration of the FDA has called for a reconsideration of approval procedures for certain vaccines, including for influenza -- proposed federal policy changes under President Donald Trump that have triggered widespread alarm among public health and medical professionals.
Moderna, a US company, said the agency's top vaccine regulator, Vinay Prasad, wrote in a letter that Moderna's clinical trial was not "adequate and well-controlled," and had not tested its experimental shot against the best product on the market.
In the large trial Moderna had compared its new vaccine with Fluarix, an approved flu shot from the company GSK.
Moderna said the rejection was "inconsistent with previous written communications" with the FDA branch that regulates biological products, including vaccines, known by the acronym CBER.
The decision "did not identify any safety or efficacy concerns with our product" and "does not further our shared goal of enhancing America's leadership in developing innovative medicines," Moderna CEO Stephane Bancel said in the statement.
"It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting."
Moderna said it had received a Refusal-to-File letter, which would indicate the application did not meet the requirements for substantive review. The company said it had requested a meeting to discuss the decision.
The letter did not identify any safety or efficacy concerns regarding the mRNA vaccine, said Moderna, which added the shot was accepted for review in the European Union, Canada and Australia.
During his first term Trump called mRNA technology a "modern-day miracle."
It was used during the Covid-19 pandemic to swiftly develop an immunization against the fast-spreading illness, and was credited with saving millions of lives.
Vaccines against Covid-19 are considered safe and effective by global health authorities, and protect against the most severe forms of the infection.
But in his second term, Trump has appointed Robert F. Kennedy Jr as his health chief, and the long-time vocal vaccine skeptic has spent the past year reshaping federal health agencies in his image.
That has meant spreading false information and sowing doubt about the safety and efficacy of vaccines widely known to be safe, and upending the pediatric immunization schedule.
Notably, Kennedy cut off federal research grants that funded mRNA development.
F.Wilson--AT